{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:45:27Z","timestamp":1790282727900,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["Frontline of Communities in the United States"],"award-info":[{"award-number":["Frontline of Communities in the United States"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA045713"],"award-info":[{"award-number":["R01DA045713"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["P30MH116867"],"award-info":[{"award-number":["P30MH116867"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Blood-borne viral infections, such as HIV and hepatitis C (HCV), are common infections among people who inject drugs (PWID). This study aims to determine the prevalence of HIV and HCV infection among PWID accessing the first legal syringe services program (SSP) in the state of Florida, along with examining baseline correlates of HIV and HCV infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Baseline behavioral enrollment assessments of 837 participants accessing an SSP for the first time were analyzed. Patients self-reporting or testing HIV or HCV positive at the enrollment visit were included. Socio-demographic, drug use, and injection-related risk behaviors in the last 30\u2009days were compared across groups defined by all combinations of HIV and HCV serostatus.<\/jats:p>\n                <jats:p>Bivariate and multivariable logistic regression models were used to assess correlates of baseline HCV and HIV infection independently.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall prevalence for HCV and HIV infection were 44.4% and 10.2%, respectively. After adjusting for confounders, the most significant correlates of baseline HCV infection were age (aOR\u2009=\u20091.01), lower education level (aOR\u2009=\u20091.13), currently homeless (aOR\u2009=\u20091.16), injecting more than seven times a day (aOR\u2009=\u20091.14), reusing syringes (aOR\u2009=\u20091.18), and sharing injection equipment (aOR\u2009=\u20091.13). The most significant predictors of baseline HIV infection were age (aOR\u2009=\u20091.01), non-Hispanic Black race (aOR\u2009=\u20091.28), Hispanic ethnicity (aOR\u2009=\u20091.12), gay or bisexual orientation (aOR\u2009=\u20091.22), and methamphetamine injection (aOR\u2009=\u20091.22). In addition, heroin injection (aOR\u2009=\u20090.92) was significantly associated with a lower odds of HIV infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion\/conclusion<\/jats:title>\n                <jats:p>Baseline behavioral predictors differed between HIV infection and HCV infection among participants accessing syringe services. Understanding the risk factors associated with each infection should be considered when developing additional harm reduction interventions tailored for diverse PWID populations served at SSPs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-020-00385-0","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T15:01:31Z","timestamp":1592233291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Baseline prevalence and correlates of HIV and HCV infection among people who inject drugs accessing a syringe services program; Miami, FL"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9384-0812","authenticated-orcid":false,"given":"Tyler S.","family":"Bartholomew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Onugha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Scaramutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardik","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Feaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansel E.","family":"Tookes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"385_CR1","volume-title":"HIV surveillance report, 2018","author":"CDC","year":"2019","unstructured":"CDC. HIV surveillance report, 2018. 2019 [cited 2019 November 29th]."},{"issue":"7","key":"385_CR2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","volume":"16","author":"L Platt","year":"2016","unstructured":"Platt L, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797\u2013808.","journal-title":"Lancet Infect Dis"},{"key":"385_CR3","unstructured":"CDC. Surveillance for viral hepatitis, United States, 2017. 2019 [cited 2019 November 5th]; Available from: https:\/\/www.cdc.gov\/hepatitis\/statistics\/2017surveillance\/index.htm."},{"issue":"12","key":"385_CR4","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192\u2013207.","journal-title":"Lancet Glob Health"},{"key":"385_CR5","unstructured":"Health, F.D.o. HIV\/AIDS section persons living with an HIV diagnosis. Available from: http:\/\/www.floridahealth.gov\/diseases-and-conditions\/aids\/surveillance\/index.html."},{"issue":"1","key":"385_CR6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1186\/s12889-016-3545-4","volume":"16","author":"B Wenz","year":"2016","unstructured":"Wenz B, et al. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011\u201314). BMC Public Health. 2016;16(1):927.","journal-title":"BMC Public Health"},{"issue":"10","key":"385_CR7","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1097\/QAD.0000000000000298","volume":"28","author":"P Patel","year":"2014","unstructured":"Patel P, et al. Estimating per-act HIV transmission risk: a systematic review. AIDS (London, England). 2014;28(10):1509.","journal-title":"AIDS (London, England)"},{"issue":"4","key":"385_CR8","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1097\/QAI.0000000000002062","volume":"81","author":"LJ Ball","year":"2019","unstructured":"Ball LJ, et al. Sharing of injection drug preparation equipment is associated with HIV infection: a cross-sectional study. J Acquir Immune Defic Syndr. 2019;81(4):e99\u2013e103.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"385_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/infdis\/jis677","volume":"207","author":"J Doerrbecker","year":"2013","unstructured":"Doerrbecker J, et al. Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment. J Infect Dis. 2013;207(2):281\u20137.","journal-title":"J Infect Dis"},{"issue":"7","key":"385_CR10","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1086\/656212","volume":"202","author":"E Paintsil","year":"2010","unstructured":"Paintsil E, et al. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis. 2010;202(7):984\u201390.","journal-title":"J Infect Dis"},{"issue":"17","key":"385_CR11","first-page":"453","volume":"64","author":"JE Zibbell","year":"2015","unstructured":"Zibbell JE, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged \u226430\u2009years\u2014Kentucky, Tennessee, Virginia, and West Virginia, 2006\u20132012. MMWR. 2015;64(17):453.","journal-title":"MMWR"},{"issue":"4","key":"385_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/00005792-199507000-00005","volume":"74","author":"DL Thomas","year":"1995","unstructured":"Thomas DL, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine. 1995;74(4):212\u201320.","journal-title":"Medicine"},{"issue":"12","key":"385_CR13","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1086\/588297","volume":"46","author":"JJ Amon","year":"2008","unstructured":"Amon JJ, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994\u20132004. Clin Infect Dis. 2008;46(12):1852\u20138.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"385_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.drugalcdep.2005.11.015","volume":"83","author":"SA Strathdee","year":"2006","unstructured":"Strathdee SA, et al. Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: results from a community-based behavioral intervention trial. Drug Alcohol Depend. 2006;83(3):225\u201332.","journal-title":"Drug Alcohol Depend"},{"issue":"9068","key":"385_CR15","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/S0140-6736(96)11380-5","volume":"349","author":"SF Hurley","year":"1997","unstructured":"Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet. 1997;349(9068):1797\u2013800.","journal-title":"Lancet"},{"issue":"16","key":"385_CR16","first-page":"1","volume":"1","author":"SA Strathdee","year":"2001","unstructured":"Strathdee SA, Vlahov D. The effectiveness of needle exchange programs: a review of the science and policy. AID Sci. 2001;1(16):1\u201333.","journal-title":"AID Sci"},{"issue":"5","key":"385_CR17","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s10900-017-0325-8","volume":"42","author":"S Reif","year":"2017","unstructured":"Reif S, et al. State of HIV in the US Deep South. J Community Health. 2017;42(5):844\u201353.","journal-title":"J Community Health"},{"issue":"6","key":"385_CR18","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.2105\/AJPH.2008.139931","volume":"99","author":"LR Metsch","year":"2009","unstructured":"Metsch LR, et al. Hospitalized HIV-infected patients in the era of highly active antiretroviral therapy. Am J Public Health. 2009;99(6):1045\u20139.","journal-title":"Am J Public Health"},{"issue":"21","key":"385_CR19","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1056\/NEJM199411243312106","volume":"331","author":"BR Edlin","year":"1994","unstructured":"Edlin BR, et al. Intersecting epidemics--crack cocaine use and HIV infection among inner-city young adults. N Engl J Med. 1994;331(21):1422\u20137.","journal-title":"N Engl J Med"},{"issue":"2","key":"385_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1023\/B:JOHE.0000016716.99847.9b","volume":"29","author":"TT Sharpe","year":"2004","unstructured":"Sharpe TT, et al. Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J Community Health. 2004;29(2):117\u201327.","journal-title":"J Community Health"},{"issue":"4","key":"385_CR21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2105\/AJPH.2019.305527","volume":"110","author":"CM Jones","year":"2020","unstructured":"Jones CM, et al. Resurgent methamphetamine use at treatment admission in the United States, 2008\u20132017. Am J Public Health. 2020;110(4):509\u201316.","journal-title":"Am J Public Health"},{"key":"385_CR22","volume-title":"Florida Comprehensive Drug Abuse Prevention and Control Act Fla. Stat. \u00a7 893.01","author":"Florida","year":"2019","unstructured":"Florida, Florida Comprehensive Drug Abuse Prevention and Control Act Fla. Stat. \u00a7 893.01. 2019."},{"key":"385_CR23","volume-title":"Florida Infectious Disease Elimination Act, ch. 2019-143, 2019 Fla. Laws 1887 (to be codified at Fla. Stat. \u00a7 381.0038)","author":"Florida.Laws","year":"2019","unstructured":"Florida.Laws, Florida Infectious Disease Elimination Act, ch. 2019-143, 2019 Fla. Laws 1887 (to be codified at Fla. Stat. \u00a7 381.0038). 2019."},{"issue":"2","key":"385_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, et al. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"4","key":"385_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4269\/ajtmh.2002.66.389","volume":"66","author":"C-S Wang","year":"2002","unstructured":"Wang C-S, et al. Comparison of hepatitis B virus and hepatitis C virus prevalence and risk factors in a community-based study. Am J Trop Med Hyg. 2002;66(4):389\u201393.","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"385_CR26","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/00004836-200204000-00021","volume":"34","author":"RC Cheung","year":"2002","unstructured":"Cheung RC, et al. Viral hepatitis and other infectious diseases in a homeless population. J Clin Gastroenterol. 2002;34(4):476\u201380.","journal-title":"J Clin Gastroenterol"},{"issue":"7","key":"385_CR27","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/aje\/155.7.645","volume":"155","author":"LE Thorpe","year":"2002","unstructured":"Thorpe LE, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155(7):645\u201353.","journal-title":"Am J Epidemiol"},{"issue":"9","key":"385_CR28","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1365-2893.2007.00855.x","volume":"14","author":"M Hickman","year":"2007","unstructured":"Hickman M, et al. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepat. 2007;14(9):645\u201352.","journal-title":"J Viral Hepat"},{"issue":"1","key":"385_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2105\/AJPH.91.1.42","volume":"91","author":"H Hagan","year":"2001","unstructured":"Hagan H, et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91(1):42.","journal-title":"Am J Public Health"},{"key":"385_CR30","unstructured":"Muth\u00e9n LK, Muthen B. Mplus user\u2019s guide: statistical analysis with latent variables, user\u2019s guide: Muth\u00e9n & Muth\u00e9n; 2017."},{"issue":"2-3","key":"385_CR31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.drugalcdep.2006.12.035","volume":"89","author":"RN Bluthenthal","year":"2007","unstructured":"Bluthenthal RN, et al. Higher syringe coverage is associated with lower odds of HIV risk and does not increase unsafe syringe disposal among syringe exchange program clients. Drug Alcohol Depend. 2007;89(2-3):214\u201322.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"385_CR32","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2105\/AJPH.2009.178467","volume":"100","author":"T Kerr","year":"2010","unstructured":"Kerr T, et al. Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health. 2010;100(8):1449\u201353.","journal-title":"Am J Public Health"},{"issue":"6","key":"385_CR33","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/dar.12276","volume":"34","author":"SG Sherman","year":"2015","unstructured":"Sherman SG, et al. Consequences of a restrictive syringe exchange policy on utilisation patterns of a syringe exchange program in Baltimore, Maryland: implications for HIV risk. Drug Alcohol Rev. 2015;34(6):637\u201344.","journal-title":"Drug Alcohol Rev"},{"issue":"5","key":"385_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.5694\/j.1326-5377.1999.tb140325.x","volume":"170","author":"N Crofts","year":"1999","unstructured":"Crofts N, Aitken CK, Kaldor JM. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust. 1999;170(5):220\u20131.","journal-title":"Med J Aust"},{"issue":"7265","key":"385_CR35","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/bmj.321.7265.899","volume":"321","author":"N Crofts","year":"2000","unstructured":"Crofts N, et al. Minimising harm from hepatitis C virus needs better strategies. Bmj. 2000;321(7265):899.","journal-title":"Bmj"},{"issue":"2","key":"385_CR36","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1177\/1073110518782949","volume":"46","author":"K James","year":"2018","unstructured":"James K, Jordan A. The opioid crisis in black communities. J Law Med Ethics. 2018;46(2):404\u201321.","journal-title":"J Law Med Ethics"},{"issue":"4","key":"385_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.annepidem.2017.02.003","volume":"27","author":"KL Hess","year":"2017","unstructured":"Hess KL, et al. Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol. 2017;27(4):238\u201343.","journal-title":"Ann Epidemiol"},{"key":"385_CR38","doi-asserted-by":"publisher","first-page":"102716","DOI":"10.1016\/j.drugpo.2020.102716","volume":"78","author":"TS Bartholomew","year":"2020","unstructured":"Bartholomew TS, et al. Examining risk behavior and syringe coverage among people who inject drugs accessing a syringe services program: a latent class analysis. Int J Drug Policy. 2020;78:102716.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"385_CR39","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/01.qai.0000166375.16222.eb","volume":"40","author":"SF Morin","year":"2005","unstructured":"Morin SF, et al. Predicting HIV transmission risk among HIV-infected men who have sex with men: findings from the healthy living project. J Acquir Immune Defic Syndr. 2005;40(2):226\u201335.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"385_CR40","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/QAI.0000000000000888","volume":"71","author":"M Hoenigl","year":"2016","unstructured":"Hoenigl M, et al. Clear links between starting methamphetamine and increasing sexual risk behavior: a cohort study among men who have sex with men. J Acquir Immune Defic Syndr. 2016;71(5):551.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"385_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/1359105314522675","volume":"21","author":"PN Halkitis","year":"2016","unstructured":"Halkitis PN, Levy MD, Solomon TM. Temporal relations between methamphetamine use and HIV seroconversion in gay, bisexual, and other men who have sex with men. J Health Psychol. 2016;21(1):93\u20139.","journal-title":"J Health Psychol"},{"issue":"1","key":"385_CR42","doi-asserted-by":"publisher","first-page":"19273","DOI":"10.7448\/IAS.18.1.19273","volume":"18","author":"NT Thu Vu","year":"2015","unstructured":"Thu Vu NT, Maher L, Zablotska I. Amphetamine-type stimulants and HIV infection among men who have sex with men: implications on HIV research and prevention from a systematic review and meta-analysis. J Int AIDS Soc. 2015;18(1):19273.","journal-title":"J Int AIDS Soc"},{"key":"385_CR43","doi-asserted-by":"publisher","first-page":"102725","DOI":"10.1016\/j.drugpo.2020.102725","volume":"79","author":"P Davidson","year":"2020","unstructured":"Davidson P, Chakrabarti P, Marquesen M. Impacts of mandated data collection on syringe distribution programs in the United States. Int J Drug Policy. 2020;79:102725.","journal-title":"Int J Drug Policy"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-020-00385-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-020-00385-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-020-00385-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T23:13:17Z","timestamp":1623280397000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-020-00385-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1186\/s12954-020-00385-0","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"20 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no competing interests to report for this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}